Dabrafenib, the mutant BRAF-selective inhibitor of BRAF kinase, issafe for treating solid tumors and shows antitumor activity againstVal600-mutant BRAF melanomas and other solid tumors, includingmelanomas that have metastasized to the brain, according to a studypublished in the May 19 issue of The Lancet . MONDAY, May 21 (HealthDay News) -- Dabrafenib, the mutantBRAF-selective inhibitor of BRAF kinase, is safe for treating solidtumors and shows antitumor activity against Val600-mutant BRAFmelanomas and other solid tumors, including melanomas that havemetastasized to the brain, according to a study published in theMay 19 issue of The Lancet . Gerald S. Falchook, M.D., from the University of Texas MD AndersonCancer Center in Houston, and colleagues used an accelerated dosetitration method with dabrafenib in a phase 1 trial of 184 adultswith incurable solid tumors (156 with metastatic melanoma) toestablish a recommended phase 2 dose. In phase 2, efficacy wasassessed in 36 patients with Val600 BRAF-mutant metastaticmelanoma, 10 patients with untreated brain metastases, and 28patients with non-melanoma solid tumors. The researchers found that, based on safety, pharmacokinetic, andresponse data, 150 mg twice daily was recommended for phase 2. Atthis dose, responses were seen in 69 percent of the patients withVal600 BRAF-mutant melanoma, including 50 percent with a confirmedresponse. Of the 27 patients with the Val600Glu BRAF mutation, 78percent responded and 56 percent had a confirmed response. Theresponses were durable, and 47 percent of patients were treated formore than six months. Of the 10 melanoma patients with brainmetastases, in nine cases the metastases shrunk. Dabrafenib alsoshowed antitumor activity against BRAF-mutant non-melanoma solidtumors. "Dabrafenib is safe in patients with solid tumors, and an activeinhibitor of Val600-mutant BRAF with responses noted in patientswith melanoma, brain metastases, and other solid tumors," Falchookand colleagues conclude. Several authors and/or their institutions disclosed financial tiesto pharmaceutical companies, including GlaxoSmithKline, whichfunded the study and manufactures dabrafenib. Abstract Full Text (subscription or payment may be required) Editorial (subscription or payment may be required) Copyright © 2012 HealthDay . All rights reserved. We are high quality suppliers, our products such as China Solar Powered Yard Lights , China Solar Powered Lawn Lights for oversee buyer. To know more, please visits Solar Lawn Lamps.
Related Articles -
China Solar Powered Yard Lights, China Solar Powered Lawn Lights,
|